Molecular imaging plays an increasingly important role in the management of endocrine tumours including diagnosis, localisation, staging and response assessment. With the increasing use of peptide receptor radionuclide therapy, the 'theranostic' role of molecular imaging - prediction of response to therapy using a diagnostic test - will be discussed, particularly focusing upon the pairing of 68Ga-DOTATATE imaging and 177Lu-DOTATATE radionuclide therapy for management of NETs. The role of dual tracer imaging characterisation of NET using FDG/DOTATATE will also be explored. Emerging next generation SSTR-targeted agents 64Cu-SARTATE and SSTR-antagonists (68Ga-DOTA-JR11) in addition to novel PET tracers including 68Ga-exendin 4 for insulinoma and 18F-DOPA for medullary thyroid carcinoma will also be discussed.